According to the most recent Form 13F filing that Victory Capital Management Inc. submitted to the Securities and Exchange Commission, the company increased its holdings in Quest Diagnostics Incorporated (NYSE: DGX) by 7.0% during the third quarter. This data was taken directly from the company’s most recent financial statements (SEC). The fund’s total number of shares in the medical research company’s common stock is now 3,223,518 after purchasing an additional 210,961 shares of the company’s stock during the quarter. Quest Diagnostics is the investment that Victory Capital Management Inc. considers its 17th most important holding, responsible for approximately 0.5% of the total value of the company’s portfolio. According to the most recent document that Victory Capital Management Inc. submitted to the SEC, the company held 2.83% of Quest Diagnostics’ stock, which had a value of $395,494,000 at the time of the filing.
There have been additional large investors who have made adjustments to their holdings in the company, and these adjustments have been made recently. The Healthcare of Ontario Pension Plan Trust Fund acquired an additional 8.7% of Quest Diagnostics’ stock during the first three months of 2018, bringing the total percentage of its stock to 98.3%. The Healthcare of Ontario Pension Plan Trust Fund now has a total of 6,921 shares of the company following the purchase of an additional 556 shares during the most recent quarter. The current market value of the Healthcare of Ontario Pension Plan Trust Fund’s holdings is $947,000. During the first quarter, Panagora Asset Management Inc. grew its holdings of Quest Diagnostics stock by a factor of 97.5% to a total of 1.1 million shares. After making an additional purchase of 3,889 shares during the most recent fiscal quarter, Panagora Asset Management Inc. now has a total of 7,878 shares of the medical research company’s stock, which have a combined value of $1,078,000. This brings the total number of shares the company owns to 7,878. During the first three months of this year, the Commonwealth of Pennsylvania Public School Employees Retirement System increased the amount of Quest Diagnostics stock owned by 3.4%. The Commonwealth of Pennsylvania Public School Employees Retirement System currently owns 15,923 shares in the medical research company. The current market value of these shares is $2,179,000. This is because the company purchased an additional 525 shares during the most recent fiscal quarter. In the first three months of 2018, Sei Investments Company made a 21.9% investment in Quest Diagnostics, which increased the percentage of the company’s stock that it owned. Sei Investments Co. now owns a total of 191,048 shares of the medical research company’s stock, which has a value of $26,165,000 after purchasing an additional 34,364 shares of the company’s stock during the most recent quarter. This brings the total number of shares that Sei Investments Co. During the first three months of 2018, Aviva PLC increased the proportion of Quest Diagnostics stock that is owned by 22.1%. Aviva PLC is now the direct owner of 68,068 shares in the medical research company. This is a result of the company’s most recent fiscal quarter, during which it purchased an additional 12,298 shares. The current value of the company’s shares is $9,360,000. At present, other types of institutional investors, such as hedge funds, hold 88.79% of the company’s shares.
In several recent research investigations, DGX has been discussed as part of the topic. Robert W. Baird upgraded their rating for Quest Diagnostics from “neutral” to “buy” in a study that was made public on Thursday. Additionally, they increased their price objective for the company’s stock from $143,000 to $154,000. These changes were based on the study’s findings discussed as part of the topic. Robert W. Baird upgraded their rating for Quest Diagnostics from “neutral” to “buy” in a study that was made public on Thursday.
Additionally, they increased their price objective for the company’s stock from $143,000 to $154,000. Both of these changes were based on the study’s findings. William Blair reaffirmed their “outperform” recommendation on shares of Quest Diagnostics in a research report published on Thursday, October 20. Morgan Stanley upgraded the stock from an “equal weight” rating to a “market performed” rating and increased their price target on Quest Diagnostics shares from $146.0 to $158.0 in a research report published on Friday, January 6. In addition to that, the price that was projected to be reached was increased to $158.0 from $146.0. In a research note published on December 14, Mizuho raised the “buy” rating and price target of $160.00 that it had previously placed on Quest Diagnostics to $165.00. In addition, the price target remained the same. In a report made public on Friday, October 21, Deutsche Bank Aktiengesellschaft changed their rating of Quest Diagnostics from “hold” to “buy” and raised their price target on the stock from $129.00 to $140.00.
Additionally, they increased their price target on Quest Diagnostics’s stock from $129.00 to $140.00. Four financial experts have provided the company with a recommendation to buy its stock, six analysts have provided a recommendation to hold their shares, and one analyst has provided a recommendation to sell their shares. According to the data from Bloomberg, the current recommendation for Quest Diagnostics is “Hold,” and the price target has been set at $150.00. In addition, the price target was recently increased from $125.00.
On Monday, the price at which trading on the NYSE DGX got underway was $147.94. A market value of $16.85 billion and a beta value of 0.98 have been assigned to the business. A beta value of 0.98 and a market value of $16.85 billion are both associated with NY. The company has a price-to-earnings ratio of 14.55. The ratio of current assets to total assets is 1.46; the ratio of quick assets to current assets is 1.34; and the ratio of total assets to current assets is 0.63. The moving average of the company’s stock price over the past 50 days is $151.02, and the moving average over the last 200 days is $138.82. The stock of Quest Diagnostics Incorporated hit a 52-week low of $120.40 and a 52-week high of $156.34 during the company’s most recent trading session.
On Thursday, October 20, the most recent quarterly earnings report for Quest Diagnostics (NYSE: DGX) was released. This report covered the company’s performance over the past three months. The medical research company reported that its earnings per share (EPS) for the quarter came in at $2.36, which was $0.19 higher than the analysts’ estimates. The company’s actual sales for the most recent quarter came in at a staggering $2.49 billion, which compares to the general forecast of $2.34 billion for sales for the company’s most recent quarter. The return on equity for Quest Diagnostics was reported at 21.36 percent, and the company’s net margin came in at 12 percent. The quarterly sales of the company experienced a decrease of 10.4% when compared to the same quarter in the previous year’s financial year. The company had earnings of $3.96 per share during the corresponding quarter of the prior year. Quest Diagnostics Incorporated is expected to generate earnings of $9.85 per share for the current fiscal year, according to projections made by market analysts.
In addition, the corporation has announced the payment of a quarterly dividend, scheduled to take place on February 1 of this year. Shareholders whose ownership was recorded as January 18 will be eligible to receive a $0.66 dividend payment. The dividend will be withheld from shareholder accounts beginning Tuesday, January 17. This translates to a yield of 1.78% and a dividend payment of $2.64 yearly for every shareholder. At this time, Quest Diagnostics has a payout ratio that comes in at 25.96%.
Besides this, Chief Administrative Officer Michael J. Deppe completed a transaction on October 26 that involved the sale of 15,497 shares of the company’s stock. The purchase of each share occurred at an average price of $145.00 throughout the sale, which resulted in the total value of the transaction being $2,247,065.00. After the deal’s completion, the chief accounting officer will directly possess 32,013 shares of the company, each of which has a value of $4,641,885, which brings the total value of the CFO’s holdings to $4,641,885. You will be taken to a document submitted to the Securities and Exchange Commission if you select this link and click on it. This document contains additional information about the transaction. Catherine T. Doherty, senior vice president of Quest Diagnostics, was said to have sold 40,765 shares of company stock on November 28. This information comes as part of other recent developments involving Quest Diagnostics. The stock sale resulted in total revenue of $6,081,322.70, with the average price at which each share was sold being $149.18. The company’s senior vice president is now the direct owner of 67,733 shares of the company’s stock, which together have a value of $10,104,408.94 as a direct result of the transaction. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC regarding the transaction, which is currently available. Besides this, Chief Administrative Officer Michael J. Deppe completed a transaction on October 26 that led to the sale of 15,497 shares. The stock was sold for a total value of $2,247,065.00, corresponding to an average price of $145.00 per share received. Because of the transaction, the chief accounting officer now owns 32,013 company shares with a combined value of $4,641,885. The disclosure about the purchase can be found in this particular location. Insiders of the company sold 60,287 shares over the preceding three months, bringing in total revenue of $8,925,320 due to these sales. 1.70 company insiders own a percent of the total number of shares in the company.